F10 and cancer: In a smaller clinical trial with a similar patient profile to Hokusai VTE Cancer study, Young et al. published the results of SELECT-D trial in which they compared oral Factor Xa inhibitor (rivaroxaban) with low-molecular-weight heparin in cancer patients with VTE.